EMA panel recommends label extension of AstraZeneca’s Imfinzi in non-small cell lung cancer

pharmafile | December 15, 2020 | News story | Manufacturing and Production, Sales and Marketing AstraZeneca, Europe, Imfinzi, NSCLC 

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has backed a new dosing regimen of AstraZeneca’s Imfinzi (durvalumab) in the treatment of locally advanced, unresectable non-small cell lung cancer (NSCLC), recommending the drug be made available in the European Union in a 1,500mg fixed dose every four weeks rather than every two weeks.

The label extension only applies to NSCLC patients in whom more than 1% of their tumour cells express PD-L1 and who have seen their disease halted through platinum-based chemoradiation therapy (CRT).

The decision was built on previous Phase 3 data supporting the previous approval of Imfinzi when administered in a 10mg/kg dose every two weeks, and incorporated positive Phase 3 findings supporting the drug’s use every four weeks for the maintenance of extensive-stage NSCLC.  

“The four-week dosing regimen will decrease the risk of exposure to infection in the healthcare setting, furthering our efforts to ensure continuity of care for cancer patients at high risk of complications during the pandemic,” remarked AstraZeneca’s José Baselga, Executive Vice President, Oncology R&D. “We look forward to offering non-small cell lung cancer patients in Europe an option that would reduce medical visits by extending dosing from two to four weeks.”

The decision follows recent approval of Imfinzi from the FDA in November in the same indication.

Matt Fellows

Related Content

BioInvent receives Investigational New Drug approval for monoclonal antibody BI-1910

Swedish clinical stage biotech company BioInvent has announced that it has received Investigational New Drug …

Bristol Myers Squibb’s NDA accepted by FDA

Global pharmaceutical company Bristol Myers Squibb (BMS) has announced that its New Drug Application (NDA) …


AstraZeneca’s Ultomiris approved in Japan for prevention of relapses in patients with NMOSD

AstraZeneca has announced that Ultomiris (ravulizumab) has been approved in Japan as a long-acting C5 …

Latest content